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Background: Mass drug administration (MDA) of ivermectin to humans for control and elimination of filarial
parasites can kill biting malaria vectors and lead to Plasmodium transmission reduction. This study examines the
degree and duration of mosquitocidal effects resulting from single MDAs conducted in three different West African
countries, and the subsequent reductions in parity and Plasmodium sporozoite rates.
Methods: Indoor-resting, blood-fed and outdoor host-seeking Anopheles spp. were captured on days surrounding
MDAs from 2008–2013 in Senegalese, Liberian and Burkinabé villages. Mortality was assessed on a portion of the indoor
collection, and parity status was determined on host-seeking mosquitoes. The effect of MDA was then analysed against
the time relative to the MDA, the distributed drugs and environmental variables.
Results: Anopheles gambiae survivorship was reduced by 33.9% for one week following MDA and parity rates were
significantly reduced for more than two weeks after the MDAs. Sporozoite rates were significantly reduced by >77% for
two weeks following the MDAs in treatment villages despite occurring in the middle of intense transmission seasons.
These observed effects were consistent across three different West African transmission dynamics.
Conclusions: These data provide a comprehensive and crucial evidence base for the significant reduction in malaria
transmission following single ivermectin MDAs across diverse field sites. Despite the limited duration of transmission
reduction, these results support the hypothesis that repeated MDAs with optimal timing could help sustainably control
malaria as well as filarial transmission.
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Anopheles gambiae, Survival, Parity, EnvironmentBackground
Despite substantial efforts dedicated to control and elim-
inate malaria from certain regions, it is still a major public
health issue. In 2012 nearly 207 million cases occurred
with approximately 627,000 deaths, 77% of which were
children younger than five years of age [1]. Current recom-
mendations to combat malaria include artemisinin-based
combination therapy (ACT) and long-lasting insecticidal* Correspondence: haoues.alout@colostate.edu
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unless otherwise stated.nets (LLIN), supported by indoor-residual spraying of in-
secticide (IRS) and intermittent preventive treatment dur-
ing pregnancy. Deployment of these strategies has fostered
important reductions of malaria-associated morbidity and
mortality in settings with moderate-to-high transmission
levels in sub-Saharan Africa [2]. However, widespread in-
secticide resistance in vectors [3], increasing malaria cases
in some African countries [1,4], and concern over spread-
ing artemisinin resistance [5], underlie the fragility of mal-
aria prevention and control. To ensure the success of
malaria elimination, the Roll Back Malaria Partnership and
Malaria Eradication Research Agenda (malERA) consulta-
tive vector control group emphasized the need to searchtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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developing new insecticides with novel modes of action,
developing effective control methods for outdoor-feeding
and resting vectors, and sustaining and integrating novel
interventions in order to significantly decrease and even
interrupt disease transmission in endemic areas.
Ivermectin is an endectocide that has been exten-
sively used alone for decades for the control of oncho-
cerciasis, or in combination with albendazole for the
elimination of lymphatic filariasis. Currently, more than
300 million individuals living in areas endemic for filar-
ial infections are treated each year in mass drug admin-
istration (MDA) campaigns [7]. The drug has an
excellent safety profile in humans and can be lethal to
mosquitoes when they feed on treated humans. Iver-
mectin MDA addresses specific malERA recommenda-
tions including: a) a different mode of action from
current insecticides; b) it targets all biting vectors, re-
gardless of their ecology and feeding behaviour; and, c)
it may be integrated into existing strategies to simultan-
eously control malaria, filariasis and other neglected
tropical diseases [8]. The mosquitocidal effect of ivermec-
tin MDA has been demonstrated on several Anopheles
species from field trials [9,10]. However, subsequent ef-
fects on vector population age-structure has only been
modelled [11], and effects on vector infection rates with
Plasmodium have only been measured for a limited dur-
ation in one setting [12]. Repeated MDAs with ivermectin
have been proposed as a complementary Plasmodium
transmission control tool [10] but several knowledge gaps
need to be filled in order to fully evaluate this strategy.
Here, the effects of single ivermectin MDAs were compre-
hensively analysed across different years and in three West
African countries with distinct malaria transmission dy-
namics: Senegal, Liberia and Burkina Faso (Figure 1,
Table 1). The degree and duration of effects on mosquito
survival, parity rate and the proportion of sporozoite-
infected vectors before and after single ivermectin MDAs
in treatment villages, and in pair-matched, untreated vil-
lages, were assessed, taking into account several biotic
(species, exophily) and abiotic (environmental) factors.Methods
Ethical statement
The study has been reviewed and approved by human
subjects’ research reviews in each country (Senegal, Etude
des vecteurs du paludisme en zone onchocerquienne au
Senegal; Liberia, EC/LIBR/012/033; Burkina Faso, 28-
2013/CE-CM) in compliance with the Helsinki Declar-
ation. Informed consent was obtained from all adult and
paid mosquito collectors. Human subject research proto-
cols 11-3121H and 11-2874H were also approved by the
Colorado State University Institutional Review Board.Study sites
Mosquito sampling was conducted during five collection
periods in three West African countries: Senegal, Liberia
and Burkina Faso (Table 1). Senegal: sampling occurred
in 2008, 2009 and 2012 in the southeastern villages of
Boundacoundi, Damboucoye, Nathia, Ibel, and Ndebou.
Bed net coverage ranged from 78.2% in 2009 to 82.0% in
2012. Select villages in this region are treated by MDA
with 150 μg/kg of ivermectin alone (Mectizan®, Merck &
Co Inc) for onchocerciasis control. Liberia: sampling oc-
curred in 2013 in the village of Ngaisaikoryah (Foya Dis-
trict, Lofa County) where the bed net coverage was
38.3%. MDA was designed to control lymphatic filariasis
(LF), onchocerciasis and soil-transmitted helminths with
a combination of ivermectin (150 μg/kg) + albendazole
(400 mg) (Albenza®, GlaxoSmithKine). Burkina Faso:
sampling occurred in 2013 in the villages of Bougouriba
(Haut-Bassins region, control) and Diarkadougou East
(Sud-Ouest region, treated) where the average bed net
coverage was 42.0%. MDA was designed to control LF
with a combination of ivermectin (150 μg/kg) + albenda-
zole (400 mg). MDA coverage rates in treatment villages
were 82.1-84.0% in Senegal, 76.2% in Liberia and 83.0%
in Burkina Faso, and were recorded either directly by in-
vestigators or provided by health authorities.
Mosquito collections and processing
Mosquito collections were performed by aspiration of
indoor-resting, blood-fed mosquitoes on select morn-
ings, as described by Sylla et al. [10]. Collected blood-
fed females were kept in field insectaries, which were
designated rooms of houses that had screened and slat-
ted windows so that they naturally fluctuated with the
ambient temperature and humidity. Temperature and
relative humidity were monitored daily every 15 minutes
in insectaries using a HOBO® device (Onset Computer
Corporation) to determine the daily fluctuation of
temperature and hygrometry, respectively. A subset of
approximately 50 fully engorged Anopheles gambiae s.l.
was transferred into cardboard cups covered with a
mesh with access ad libitum to a sugar solution for sur-
vival analysis. Dead mosquitoes were counted daily, re-
moved from cups over five consecutive days and
identified morphologically to species. The head + thora-
cies of mosquitoes that survived after five days were
stored individually in 1.5-ml tubes containing desiccant.
Remaining collected mosquitoes were dissected on the
same day of capture and head + thoracies were stored
individually in 1.5-ml tubes with desiccant.
Additionally, outdoor host-seeking mosquitoes were cap-
tured over the night prior to morning house aspirations by
either human-landing catch or tent traps, as previously de-
scribed in Krajacich et al. [14]. These were identified mor-
phologically to species and dissected for head + thoracies
Figure 1 Study sites outlined on maps showing the spatial distribution of the Plasmodium falciparum entomological inoculation rate
(PfEIR) in Africa (panel A), Burkina Faso (B), Senegal (C) and Liberia (D) in 2010. Red squares represent the location of the sampled villages.
Data are available at Malaria Atlas Project [13].
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these mosquitoes was also used for parity analysis.
Parity determination
Age grading of An. gambiae s.l. was determined by parity
analysis in samples from Senegal 2012 and from BurkinaTable 1 Characteristics of study sites
Country Phytogeographic zone Rainy season Ma
Burkina Faso Sudanian June-October Hy
Liberia Tropical rainforest Year round Ho
Senegal Sudano-Guinean May-October HyFaso 2013. A random batch of approximately 20 females
from each village and each sampling day was dissected for
their ovaries. Ovaries were dissected in water under a light
microscope and allowed to dry. Parity rate was determined
by observing the presence of coiled or uncoiled ovarian
tracheoles [15].laria endemicity MDA treatment Diseases targeted
perendemic IVM + ALB LF
lo-endemic IVM + ALB LF, NTD, onchocerciasis,
perendemic IVM Onchocerciasis
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detection
DNA was extracted with the Qiagen DNeasy kit and was
used to identify the species in the An. gambiae complex
[16]. DNA from individual head + thoraxes were tested
by Taqman polymerase chain reaction for Plasmodium
spp. sporozoite detection [17], which used laboratory-
confirmed Plasmodium falciparum sporozoite-infected
An. gambiae s.s., as positive controls.
Statistical analysis
Mosquito survivorship
Anopheles gambiae survivorship was analysed using a
generalized linear mixed-effect model with a binomial
error structure to compare the effect of MDA between
West African countries. The effect of eight variables on
mosquito survivorship was analysed. These included the
categorical variables field sites (Senegal 2008, 2009-mid
season and 2009-end season, Liberia 2013 and Burkina
Faso 2013), the village (treated or control), the treatment
type (ivm or ivm + alb), the species, the collection (in-
door or outdoor), the numerical variables temperature
and hygrometry fluctuations (i.e., the difference between
the maximum and the minimum values on each sam-
pling day), and time relative to MDA date. The binary
response variable was mosquito survivorship, counted as
either dead or alive for each individual on the third day
post-capture, when the maximal reduction in mosquito
survivorship is observed [18]. Two types of analyses
were performed: one to compare the difference in sur-
vival rate over time (in weeks) between treated and con-
trol villages and another to characterize the difference in
survival rate over time (in weeks) between the treatment
types. The first analysis was performed on all data ob-
tained from Senegal and Burkina Faso only because
there were no untreated villages during the sampling
period in Liberia. This analysis included data from 3,140
An. gambiae s. l. and tested the influence of the site, vil-
lage, species, collection, temperature and hygrometry
fluctuations and time. The second analysis included data
from 1,370 An. gambiae s.l., collected from treated vil-
lages only (including Ngaisakoryah, Liberia) and col-
lected after the date of drug distribution only, and tested
the influence of site, treatment type, species, collection,
temperature and hygrometry fluctuation and time. The
site variable was used as a random variable to account for
the nested data structure, i.e., the correlation between in-
dividuals from the same field site. For each analysis, the
random structure was selected and compared with a gen-
eralized linear model with no random effect based on the
lowest Akaike’s information criterion (AIC). Statistical
analyses were performed with Statistical Analysis Software
(SAS Institute Inc., Cary, NC, USA) using the GLIMMIX
procedure. This procedure performs a type III hypothesisfor the fixed effect variables and computes the F-statistic
based on Satterthwaite’s approximation. The maximal
models included all the variables with interactions and
were subsequently simplified following a step-by-step
AIC-based procedure. Output of the minimal model was
used to produce the local regression (LOESS procedure)
with the computed 95% confidence intervals. The mean
survival rates by week were computed and compared be-
tween villages (control and treated) taking into account
multiple testing using the Bonferroni procedure.
Parity rate
Parity data were analysed weekly and significant differ-
ences in parity rate over time were assessed separately
for the control (N = 327) and the treated (N = 380) vil-
lages, and also between villages for each week, separately
(pre-MDA: N = 222, week 1: N = 130, week 2: N = 112,
week 3: N = 243) using the χ2-test. The parity data were
analysed also with a generalized linear model with a bi-
nomial error structure (GLM procedure in SAS) to pro-
duce the local regression (LOESS procedure) with the
computed 95% confidence intervals.
Sporozoite rate
Variations in sporozoite rates over time were analysed
only from data obtained in Senegal 2012, Liberia 2013
and Burkina Faso 2013 reported here. Analysis was per-
formed using a generalized linear model with a bino-
mial error structure (GLM procedure in SAS), due to
the low number of field sites included. The effect of
seven variables on mosquito sporozoite rate was ana-
lysed: site, village, species, collection as categorical vari-
ables and temperature and hygrometry fluctuations and
time relative to MDA (in weeks) as numerical variables.
The binary response variable was the status of Plasmo-
dium infection in thoraces (i.e., infected or uninfected).
The model was subsequently simplified following a
stepwise AIC-based procedure. Significance of the vari-
able retained in the minimal model was determined
using the type III test and normality of residuals was
checked. Output of the minimal model was used to
produce the local regression (LOESS procedure) with
the computed 95% confidence intervals.
Results
Effect of MDA on Anopheles gambiae survival rate
The three-day survival rate of An. gambiae s.l. collected
in each field site is summarized in Table 2 by sampling
week. The three-day survival rate was first analysed in
treated villages and compared with that from controls,
so only data from Burkina Faso and Senegal (2008 and
2009) were used because a control village in Liberia
was not sampled. The influence of field sites appeared
to be weak as the variance of the random variable site
Table 2 Three-day survival rate of wild caught Anopheles gambiae s.l. following mass drug administration of
ivermectin in the treated village compared to the control village
Study site Year Village Time relative to MDA (week)
Week −3 Week −2 Week −1 Week 1 Week 2 Week 3
Burkina Faso 2013 (Aug.-Sept.) Control 0.96 ± 0.02 (89) 0.70 ± 0.05 (70) NA 0.71 ± 0.03 (266) 0.651 ± 0.04 (129) 0.89 ± 0.05 (45)
Treated 0.85 ± 0.04 (75) 0.75 ± 0.04 (122) NA 0.50 ± 0.03 (329) 0.709 ± 0.03 (196) 0.81 ± 0.06 (41)
p-value 0.0477 0.6029 - 1.54E-07 0.3268 0.4325
Liberia 2013 (June) Control NA NA NA NA NA NA
Treated NA 0.98 ± 0.01 (104) 0.91 ± 0.04 (66) 0.42 ± 0.04 (147) 0.86 ± 0.05 (50) NA
p-value - - - - - -
Senegal 2009 (Oct.) Control NA NA 0.83 ± 0.06 (40) 0.81 ± 0.05 (62) 0.792 ± 0.08 (24) NA
Treated NA NA 0.79 ± 0.02 (338) 0.48 ± 0.04 (168) 0.75 ± 0.06 (48) NA
p-value - - 0.7879 1.5E-05 0.9218 -
2009 (July-Aug.) Control NA 0.77 ± 0.08 (26) 0.61 ± 0.09 (33) 0.72 ± 0.06 (60) 0.833 ± 0.07 (30) NA
Treated NA 0.90 ± 0.04 (59) 0.82 ± 0.03 (154) 0.57 ± 0.04 (150) 0.819 ± 0.03 (160) NA
p-value - 0.2162 0.015 0.077 1 -
2008 (Aug.) Control NA NA 0.76 ± 0.07 (37) 1.0 ± 0 (26) 0.842 ± 0.08 (19) NA
Treated NA NA 0.70 ± 0.05 (89) 0.40 ± 0.06 (70) 0.636 ± 0.15 (11) NA
p-value - - 0.6427 4.78E-07 0.4031 -
Data presented are mean survival rate ± s.e. with sample size in brackets. Significance of differences (p-value) between the control and the treated villages were
assessed using χ2 test, p-value below 0.05 are indicated in bold.
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distinct from zero. Mosquito survival rate was significantly
influenced by the variables: village (F1,3434 = 5.48, p =
0.0193), time (F2,3434 = 21.22, p < 0.001), hygrometry fluc-
tuation (F1,3434 = 9.66, p = 0.0019; Additional file 1: Figure
S1), and the interaction of village with time (F2,3434 =
13.62, p < 0.001). Neither the species nor the exophily
were retained in the minimal model. The computed
three-day survival rate of An. gambiae s.l. over time in
the treated and the control villages from all field sites
shows a reduction during the first week after MDA
from 82.3% ±2.0 in the control villages to 54.4% ±3.2 in
the treated villages (a 33.9% reduction over the three
days). Hygrometry fluctuation negatively influenced the
mosquito survival rate (Spearman correlation coeffi-
cient; −0.5253, p < 0.0001; Additional file 1: Figure S1).
Comparison of MDA treatments on the survival rate of
Anopheles gambiae
This analysis focused only on treated villages to
characterize the duration of the reduction in survival
rate post-treatment, as well as the potential effect of
the different drug regimens (either ivermectin + alben-
dazole or ivermectin alone), thus it included data from
all three ecological settings starting from the date of
MDA. As expected, the influence of time is significant
because survival rate increased over time to the pre-
treatment level (F1,1361 = 73.72, p < 0.001). Interestingly,
the effect of time was different between treatment types
(treat. type by time interaction: F1,1361 = 5.36, p = 0.0208),suggesting that the ivermectin + albendazole treatment
may have resulted in an apparent longer-lasting mos-
quitocidal effects as compared to treatment with iver-
mectin alone. However, the degree of reduction in
mosquito survival rate did not differ between treat-
ment types: from an average of 88.2% ±2.6 before
MDA to 53.44% ±3.4 for ivermectin alone, compared
to 59.69% ±2.4 for ivermectin + albendazole, the week
following MDA (p = 0.809). The hygrometry fluctu-
ation did not significantly influence the overall survival
rate (F1,1361 = 0.22, p = 0.6427), but the analysis re-
vealed a significant interaction of hygrometry variation
with treatment type (Hygro. by Treat. interaction:
F1,1361 = 5.85, p = 0.0157).
Parity rate
Figure 2 represents the variation in parity rate by week
and shows no significant variation over time in the con-
trol village (χ2df=3 = 3.96, p = 0.265, N = 327), ranging be-
tween 80 and 89.72% (mean of 85.4% ±2.3). In contrast,
the proportion of parous female An. gambiae s.l. varied
significantly over time in the treated village (χ2df=3 = 14.36,
p = 0.0024, N = 380). While 80.7% ±3.6 of host-seeking fe-
males were parous before MDA in the treatment village
and showed no significant difference with the control vil-
lage (χ2df=1 = 0.033, p = 0.856, N = 222), this proportion sig-
nificantly decreased to 60.0% ±5.6 (χ2df=1 = 4.98, p = 0.0255,
N = 130) over the first week post-MDA and to 58.0% ±7.0
(N = 50, χ2df=1 = 5.78, p = 0.0161, N = 112) over the second
week post-MDA. By the third week post-MDA, the parity
Figure 2 Mosquito parity rate over time in treated and control villages. Significant differences in parity rates between the control (blue
bars) and the treated villages (red bars) are denoted by stars above the column pairs and derived using a Chi-squared test (N.S. = not significant).
Error bars are the standard error of the mean. Sample sizes were 103 and 119 pre-MDA, 55 and 75 on week 1, 62 and 50 on week 2 and 107 and
136 on week 3 in the control and the treated villages, respectively.
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remained significantly lower than in the control villages
(χ2 df=1 = 9.05, p = 0.0026, N = 243).Sporozoite rate
A proportion of all vectors were processed on the day
of capture from Senegal 2012, Liberia 2013 and Burkina
Faso 2013 (Additional file 2: Table S1) and analysed for
sporozoite infections over time. Overall, the variable
time did not significantly influence the sporozoite rate
(χ2 df=5 = 8.198, p = 0.1456). However, the variation
across time is significantly different between villages
(time:village interaction: χ2 df=5 = 25.89, p < 0.001), in-
dicating a difference between control and treated vil-
lages. The mean sporozoite rate in the control villages
did not significantly change over time, varying from
2.71% ±0.8 to 4.84% ±0.9 (p = 1). In the treated villages,
ivermectin MDA reduced the sporozoite rate from
5.31% ±1.2 pre-MDA to 2.03% ±0.8 the first week (p =
0.0074) and to 1.19% ±0.7 the second week after MDA
(p = 0.0018). In addition, the significant site:time inter-
action (χ2 df=5 = 29.25, p < 0.001) indicated that the
variation of sporozoite rate across time is significantly
different between malaria ecologies. However, the min-
imal model did not retain the time:site:village triple
interaction, indicating that the difference between con-
trol and treated villages over time is consistent among
field sites. Interestingly, sporozoite rate was also signifi-
cantly influenced by daily temperature fluctuation (χ2
df=1 = 7.334, p = 0.0068; Additional file 3: Figure S2).Combined mosquito survival, parity and sporozoite rate
over time
Figure 3 shows the dynamic of survival, parity and sporo-
zoite rates across time (individual sampling days) relative
to the MDA date, obtained by local regression of all rele-
vant data. For most of the pre-MDA sampling dates, the
control and treated villages do not significantly differ in
survival rate (Figure 3A) and parity rate (Figure 3B) as
evidenced by overlapping 95% confidence intervals.
Over this same time interval, the mosquito sporozoite
rate (Figure 3C) from treated villages was significantly
greater than from pair-matched control villages, and
fluctuated more significantly between sites and villages,
as evidenced by more broad 95% confidence intervals,
likely due to the variable nature of human-to-mosquito
transmission. Immediately following MDA in the treated
villages, all three measures were significantly reduced in
the treated villages compared to control villages. Survival
rate in treated villages was the first measure to recover to
pre-MDA and control village values, at day 7 post-MDA.
The parity rate never recovered to pre-MDA and control
village values by the end of the sampling, but it did hit a
slower increasing plateau after 15 days post-MDA (dotted
line on the right of all graphs). On this same date post-
MDA, the sporozoite rate in treated villages recovered to
the same rate as pre-MDA and control villages.Discussion
In an attempt to comprehensively evaluate the effects
of single ivermectin MDA, alone or in combination
Figure 3 Dynamic of survival (A), parity (B), and sporozoite (C) rates across time relative to mass drug administration. Daily data points
represented as circles from control (blue) and treated (red) villages, with the computed 95% confidence intervals using the local regression
method (LOESS) in SAS software.
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on natural populations of mosquito vectors was charac-
terized in three West African countries with different
malaria ecologies. The primary first order effect of iver-
mectin MDA was on mosquito survival rate, which was
consistent across all sites. While lasting a relatively
short time (one week), the observed lethal effect of iver-
mectin on the vector population biting the villagers is
strong with respect to vectorial capacity. The calculated
reduction in daily mosquito survival rate (p) of 11%
would lead to a 78% reduction in vectorial capacity for
the week following the MDA [19]. Nonetheless, recent
modelling of the impact of ivermectin on malaria trans-
mission demonstrated that the duration of the mosqui-
tocidal effect has a greater impact than its magnitude
[20]. The two different drug regimens did not differ-
ently affect the degree of mosquito survival rate change,
suggesting no additional effect from albendazole, which
is consistent with published laboratory results [18].
While differences in field sites did not appear to
strongly influence the model, this analysis seems to in-
dicate that the ivermectin + albendazole regimen re-
sulted in a longer mosquitocidal effect compared to the
ivermectin alone regimen (significant treat. type by time
interaction). Awadzi et al. [21] found no significant dif-
ferences in ivermectin plasma pharmacokinetics when
administered with albendazole, potentially ruling out
drug-drug interactions in humans, however drug-drug
interactions in the mosquito might be a potential fac-
tor. From this study, it is not clear what is influencing
this observation and further experiments are needed to
characterize the role of other biotic or abiotic factors
affecting vector population susceptibility.
Modelling predicted that the mortality effects from a
single MDA would temporarily shift the population
structure of vector mosquitoes around treated villages
[11]. In concordance with this model, the proportion of
parous, outdoor host-seeking mosquitoes in the popula-
tions studied was reduced by 25%. This reduction is
equivalent to parity rate changes observed in An. gam-
biae populations after implementation of IRS with di-
chlorodiphenyltrichloroethane (DDT) [22] and LLIN
distribution [4]. The observed reduction in parity rate
may, in part, be due to an increased susceptibility to iver-
mectin in older mosquitoes, a phenomenon that has been
reported with the use of other insecticides, including pyre-
throids and DDT [23]. Such an effect would lead to a
greater impact on malaria transmission, as mosquito vec-
tors need to survive the extrinsic incubation period to be-
come infectious (approximately ten days). The one-week
reduction of survival rates resulted in a significant shift to
a younger mosquito population that lasted more than
three weeks after the MDA. This suggests: a) that iver-
mectin concentrations found in human blood after thefirst week could still selectively kill older and/or infected
mosquitoes, and/or, b) that the population returns to its
initial age-structure at a relatively slow speed. In line with
the first hypothesis, Kobylinski et al. showed that sublethal
concentrations of ivermectin reduced the proportion of P.
falciparum (NF-54 strain)-infected An. gambiae at both
oocyst and sporozoite stages, suggesting an increased sus-
ceptibility of infected mosquitoes [24].
Consistent across field sites, sporozoite rates were re-
duced by 77.5% for 15 days. The observed sporozoite rate
reductions is likely explained by the combination of vari-
ous ivermectin effects against factors influencing vectorial
capacity, including: a) mosquito survival rate (with pos-
sible selective effects against older and/or P. falciparum
infected adults); b) vector density relative to hosts (effects
on egg-laying ability [25]); c) time between mosquito
blood meals (refeeding frequency [18]); and, d) poten-
tial effect on vector competence (i.e., ability of vectors
to support parasite development). The change in sporo-
zoite rate over time reflects the change in parity rate
over time, suggesting that the shift of the age-structure
may be the main cause of the reduction of sporozoite
prevalence in mosquito vectors. While laboratory stud-
ies have suggested an anti-sporogonic effect (inhibition
of parasite development in the vector) [24], ongoing
semi-field and field studies examining the effect of iver-
mectin on wild-type mosquitoes and parasites will need
to sort out these discrepancies.
The limitations of this study include some unavoidable
inconsistencies in sampling and processing regimens
across each year and field site; for example, a control vil-
lage was not concomitantly sampled in Liberia. Even so,
a single ivermectin MDA has a clear and dramatic im-
pact on the proportion of infectious mosquitoes for up
to 15 days. As previously proposed, repeated ivermectin
MDAs would be necessary to have a sustained effect on
Plasmodium transmission [8,11]. Repeated ivermectin
MDAs have been shown to be safe, even at higher doses
than currently administered [26]. Such regimens also
have the potential to integrate with control of neglected
tropical diseases (NTD) such as onchocerciasis, LF,
soil-transmitted helminths (strongyloidiasis, ascariasis,
trichuriasis, and hookworm), scabies, and lice [27]. Ques-
tions remain about how frequent, repeated, ivermectin
MDAs would need to occur with respect to when in the
transmission season they would be administered. The
maximal effect would probably occur if MDAs were con-
centrated during dry-to-wet season transitions, when the
numbers of vectors are low but increasing, and thus most
susceptible to population level effects. This may also have
the most significant effect on malaria incidence, as these
transition seasons are also concomitant with peak seasonal
risk of clinical malaria in children living in hyperendemic
areas, likely due to acquisition of new Plasmodium clones
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ivermectin MDAs would reduce Plasmodium transmis-
sion, this effect alone would not reduce or eliminate
the human reservoir of Plasmodium parasites. Integra-
tion with other control measures is critical. Modelling
has shown that combining repeated ivermectin MDAs
with anti-malarial drugs (e.g., ACT) would sustain trans-
mission interruption and achieve malaria elimination [20].
Addition of albendazole with ivermectin during MDAs
would maximize impact against NTDs and help prevent
development of helminth resistance to either drug [29].
Lastly, community-directed treatment platforms for iver-
mectin delivery have been shown to more cost-effectively
and efficiently deliver LLINs [30,31]. A large-scale ran-
domized trial would be required to fully evaluate the im-
plementation of multiple control methods alone or in
combination. It would be expected that ivermectin MDAs
would synergize with LLIN and IRS control methods to
more significantly reduce the proportion of infectious vec-
tors, especially in areas where pyrethroid/DDT resistance
in vectors is common. Ivermectin MDAs might particu-
larly help to control malaria transmission from outdoor-
biting vectors that are less affected by the latter control
methods. Overall, such integrated strategies would control
many diseases simultaneously, and should lead to strong
and lasting health benefits in the treated communities.Conclusions
These data show that single ivermectin MDAs signifi-
cantly affect mosquito population survival rates, which
temporarily changes mosquito population age-structure
and results in significantly suppressed sporozoite rates
for 15 days after the MDA. The results were collected
across multiple years and diverse West African malaria
ecologies, and demonstrate a consistent effect despite
these differences. These data provide a strong evidence
base to develop repeated ivermectin MDA for malaria
control and elimination strategies, especially when in-
tegrated with complementary malaria and NTD con-
trol strategies that all can utilize the very successful
community-directed treatment models developed for
onchocerciasis and LF control.Additional files
Additional file 1: Figure S1. Correlation between Anopheles gambiae
s.l. survival rate and hygrometry fluctuation (dH). Shaded area around the
regression line is 95% CI. Spearman correlation coefficient: −0.5253, p <
0.001. Dots indicate data from distinct field sites: light green: Senegal
2008, pink: Senegal July-Aug. 2009, dark green: Senegal Oct. 2009, red:
Burkina Faso 2013.
Additional file 2: Table S1. Sporozoite-infected malaria vectors
collected indoor and outdoor. Sample sizes are indicated in brackets.
HLC, LTC refer to human-landing catch and light trap catch, respectively.Additional file 3: Figure S2. Correlation between Anopheles gambiae
s.l. sporozoite rate and temperature fluctuation (dT). Shaded area around
the regression line is 95% CI. Pearson correlation coefficient: 0.38360, p <
0.001. Dots indicate data from distinct field sites: green: Senegal 2012,
blue: Liberia 2013, red: Burkina Faso 2013.
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